Search

Filters
Clear All
  • 9

Phase

  • 3
  • 1
  • 4
  • 8
  • 8

Found 9 Gliomas trials

A listing of Gliomas medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Registering Genomics and Imaging of Tumors

J
Jason Parker
18-89 years
All genders
This research is being done to see if genetic mutations inside brain tumors can be identified using pictures from MRI or PET scanners, instead of using needles or surgery. To conduct the study, we need to take pictures of the locations of tumor samples as they are removed during surgery. …

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)

All genders
Phase 3
Interventional
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and …

Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)

M
Michael Ferguson, MD
1-17 years
All genders
The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

S
Sandeep Batra, MD
2-25 years
All genders
Phase 3
Interventional
This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or …

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

S
Sandeep Batra, MD
2-21 years
All genders
Phase 3
Interventional
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type …

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations

S
Sandeep Batra, MD
3-25 years
All genders
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations.

A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

M
Melissa Bear, MD
1-21 years
All genders
Interventional
We are conducting a pediatric phase 1 trial of single-agent intravenous CBL0137 given on Day 1 and Day 8 of a 21 day cycle in children with refractory or recurrent solid tumors, including CNS tumors and lymphoma. The study will use the rolling six design with the primary aim of …

Pediatric Long-Term Follow-up and Rollover Study

M
Michael Ferguson, MD
1-100 years
All genders
Phase 4
Interventional
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

S
Sandeep Batra, MD
1-21 years
All genders
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has …